Table 2.
Cell* type | OA | Noninflammatory ON | All inflammatory ON | Inflammatory ON w/co-morbidities | Inflammatory ON w/o co-morbidities |
---|---|---|---|---|---|
(n ≥ 9) | (n ≥ 6) | (n ≥ 11) | (n ≥ 4) | (n ≥ 6) | |
CD3+ | 108.9 (22.6) | 21.4 (13.9)†,‡,§,|| | 105 (9.5) | 91.3 (21.3) | 105 (7.2) |
CD4+ | 70.0 (11.1) | 12.5 (11.5)†,‡,§,|| | 96.3 (15.6) | 80.8 (23.7) | 111.7 (20.2) |
CD8+ | 6.9 (3.0) | 1.7 (1.4)‡,§,|| | 12.9 (2.4) | 10.5 (3.6) | 14.0 (3.7) |
CD68+ | 117.5 (22.4)|| | 45.8 (31.0)‡,|| | 179.2 (21.4) | 149.2 (43.1) | 207.5 (18.9) |
Values represent the mean relative number of each specific cell type present in each group along with the SEM in parenthesis. Values were derived by multiplying the percent staining of each antibody on each cell type by the inflammatory score. n = the number patients.
Significantly different compared to OA, p < 0.05.
Significantly different compared to all inflammatory ON, p < 0.05.
Significantly different compared to inflammatory ON w/co-morbidities, p < 0.05.
Significantly different compared to inflammatory ON w/o co-morbidities, p < 0.05.